Bhatia Rohit, Singh Nishita
Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.
Ann Indian Acad Neurol. 2019 Apr-Jun;22(2):131-136. doi: 10.4103/aian.AIAN_345_18.
Secondary progressive multiple sclerosis (SPMS) is characterized by progressive accumulation of disability without intermittent recovery. Treatment of these patients is challenging due to limited understanding of pathogenesis and fewer therapeutic options. This article summarizes difficulties in defining and conducting trials in SPMS, review major clinical trials on therapies approved and unapproved in SPMS and lastly, therapies in pipeline for use in SPMS.
继发进展型多发性硬化（SPMS）的特征是残疾持续累积且无间歇性恢复。由于对其发病机制了解有限且治疗选择较少，这些患者的治疗颇具挑战性。本文总结了SPMS试验在定义和实施方面的困难，回顾了SPMS已批准和未批准疗法的主要临床试验，最后介绍了正在研发用于SPMS的疗法。
